ImmunityBio, Inc. (NASDAQ: IBRX) has received Expanded Access authorization from the U.S. Food and Drug Administration (FDA) for its Cancer BioShield™ platform, featuring ANKTIVA® (nogapendekin alfa inbakicept-pmln). This authorization allows the treatment of lymphopenia, a life-threatening immune deficiency, in adult patients with refractory or relapsed solid tumors who have progressed after first-line standard therapies such as chemotherapy, radiation, or immunotherapy. This significant regulatory approval provides new hope for patients with solid tumors experiencing immune collapse, offering an innovative approach to cancer care by restoring lymphocyte levels and potentially altering disease progression. The positive survival outcomes observed in metastatic pancreatic cancer patients at the ASCO Annual Meeting 2025 underscore the potential impact of this treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.